Skip to main content

Sequenom Sells MassArrays to South Korean Cancer Center, Two Other Customers

NEW YORK (GenomeWeb News) — Sequenom sold three of its MassArray analyzers in South Korea in the fourth quarter of 2006, the company said today.
 
The sales were made through Bioneer, a Daejeon-based genomics research products and services company that signed an exclusive deal with Sequenom in September 2006 to market and distribute the MassArray in South Korea.  
 
Sequenom said Bioneer sold one of its analysis systems to National Cancer Center of the Republic of Korea, but did not disclose the two other customers.
 
Bioneer president and CEO Han-Oh Park said the fourth-quarter sales “represent increased demand we are seeing in South Korea for fine mapping genetic analysis solutions, and for life sciences research tools in general.”
The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.